ANAB
NASDAQ HealthcareAnaptysBio, Inc. - Common Stock
Biotechnology
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
�� 市场数据
| 价格 | $67.51 |
|---|---|
| 成交量 | 621,101 |
| 市值 | 1.94B |
| 贝塔系数 | 0.410 |
| RSI（14日） | 71.0 超买 |
| 200日均线 | $40.04 |
| 50日均线 | $59.68 |
| 52周最高 | $73.30 |
| 52周最低 | $17.11 |
| Forward P/E | -19.08 |
| Price / Book | 50.84 |
🎯 投资策略评分
ANAB 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (47/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🔪 Falling Knife (7/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ANAB in your text
粘贴任何文章、记录或帖子 — 工具将提取 ANAB 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.